Skip to main content

Table 2 Characteristics of the included studies

From: The efficacy of analgesics in controlling orthodontic pain: a systematic review and meta-analysis

Study Country Design Age (years) Sex (% female) Orthodontic treatment Interventions Evaluation
intervals
Outcome measures
Bernhardt
2001 [11]
America RCT Mean12 51% separator placement Ibuprofen(400 mg),placebo 2 h, 6 h, at night, 24 h, 2 d, 3 d, 7 d VAS
Farzanegan
2012 [12]
Iran RCT 13–18 100% archwire placement Ibuprofen(400 mg),placebo, chewing gum,soft viscoelastic wafer, and hard viscoelastic wafer 2 h, 6 h, at night, 24 h, 2 d, 3 d, 7 d VAS
Kohli
2011 [13]
India RCT 13–20 50% separator placement Ibuprofen(400 mg), placebo 2 h, 6 h, at night, 24 h, 2 d, 3 d, 7 d VAS
Minor
2009 [14]
America RCT 13–30 25% separator placement Ibuprofen(400 mg),placebo 2 h, 6 h, bedtime,awakening,24 h VAS
Patel
2011 [15]
America RCT 18–30 46% separator placement Ibuprofen, naproxen sodium, acetaminophen, placebo (OTC) 2 h, 6 h, bedtime,awakening,24 h VAS
Polat
2005 [16]
Turkey RCT 10–24 38% archwire placement Ibuprofen(400 mg),placebo, naproxen sodium 2 h, 6 h, at night, 24 h, 2 d, 3 d, 7 d VAS
Salmassian
2009 [17]
America RCT 12–18 48% separator placement Ibuprofen(400 mg),acetaminophen(600 mg),placebo 0 h,3 h, 7 h, 19 h,24 h, 31 h,48 h, 3 d,4d, 7 d VAS
Sudhakar
2014 [18]
India RCT 14–21 50% separator placement Ibuprofen(400 mg),acetaminophen(650 mg),aspirin(300 mg),placebo 2 h, 6 h, bedtime,24 h,2 d, 3 d, 7 d VAS
Gupta
2014 [19]
India RCT 15–22 49% archwire placement Acetaminophen(500 mg),
etoricoxib(60 mg), placebo
2 h, 6 h, at night, 24 h,2d,3d VAS
Eslamian 2017
[20]
Iran RCT 14–20 68% separator placement Naproxen, placebo 2 h, 6 h, 24 h,2d,3d,7d VAS
Nik 2016
[21]
Iran RCT Mean15 56% separator placement Acetaminophen(650 mg), ibuprofen(400 mg), and placebo 0 h, 2 h, 6 h, bedtime, 24 h VAS
Kaur 2019
[22]
India RCT Mean15 70% separator placement Acetaminophen(500 mg),
verbal behavior modification, placebo
6 h, 24 h,2d,3d,4d,5d,6d,7d VAS